Biotech | November 30, 2021
Thermo Fisher Scientific’s new CRISPR Genome editing protein
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
_256_384.jpg)
Destiny-Breast11 will evaluate Enhertu as a monotherapy or Enhertu followed by paclitaxel, trastuzumab and pertuzumab
It’s a two-dose vaccine administered 28 days apart
The appraisal of the applications has been carried out based on the ranking methodology laid down in the operational guidelines of the Scheme
Fyarro is the first and only approved therapy for adults for the treatment of malignant PEComa in adults
Contribution from the top five therapies stood at 58% of IPM in October 2021. These therapies are cardiac, anti-infectives, gastro-intestinal, anti-diabetic and vitamins
It is estimated that one-third of our country’s population has some form of these disorders
The approval is for Cytomegalovirus, a type of Herpes virus
Cryo-technology helps in early diagnosis and palliative care in later stages of cancer
While industry steps out of its comfort zone to innovate, the government has to support by allocating funds across research lifecycle and offer incentives for innovation
Subscribe To Our Newsletter & Stay Updated
